TECHNOLOGY

Synthetic DNA technology tailored to your needs

Do you rely on plasmid DNA for the production of your next-generation therapeutics? There is a way to avoid bottlenecks and expedite your development pipeline with cell-free synthetic DNA.

Why synthetic DNA?

As demand grows for cell & gene therapies and mRNA therapeutics, synthetic DNA provides a cleaner, faster, and more reliable path to high-quality DNA starting material. Unlike plasmid DNA, synthetic DNA can be produced rapidly without relying on bacterial fermentation, minimizing complexity and contamination risks. It also offers unparalleled flexibility and customization, allowing researchers to design exactly the sequences they need without limitations. These advantages make synthetic DNA technology increasingly attractive as the field pushes toward scalable, high-purity, and demand-responsive DNA production.

Compared to other DNA synthesis methods, such as de-novo synthesis or PCR-based amplification, synthetic DNA offers high quality, purity, flexibility and scalability. 4basebio’s synthetic DNA platform can amplify long sequences up to 20kb in length and produce large GMP batches to support advanced clinical programs. These advantages make synthetic DNA technology increasingly attractive as the field pushes toward scalable, high-purity, and demand-responsive DNA production.

Enzymatic DNA manufacturing process

4basebio’s synthetic DNA is produced using an enzymatic, cell-free manufacturing process powered by its proprietary primer-free DNA amplification technology, TruePrime®. Unlike conventional pDNA manufacturing, which relies on bacterial fermentation, cell growth, and downstream plasmid extraction, 4basebio’s approach eliminates the need for host cells entirely.

TruePrime® combines two unique enzymes to enable isothermal multiple displacement DNA amplification in a continuous, cell-free process, delivering high yields of high-quality DNA. 4basebio’s enzymes are produced in-house and have a higher fidelity compared to the wildtype, which ensures greater sequence accuracy and avoids supply chain issues.

This unique cell-free, enzymatic process offers greater control, scalability, and consistency compared to plasmid-based manufacturing, supporting reliable production of synthetic DNA tailored for advanced therapeutic applications. What makes 4basebio’s process unique is the removal of all bacterial sequences and producing our own master template before DNA amplification. This ensures no antibiotic resistance genes and unwanted plasmid DNA backbone sequences are incorporated, resulting in a cleaner and more defined DNA product.

6 blue and purple icons showing 4basebio's synthetic DNA manufacturing process. This synthetic dna technology is an enzymatic dna amplification process.

Why synthetic DNA?

As demand grows for cell & gene therapies and mRNA therapeutics, synthetic DNA provides a cleaner, faster, and more reliable path to high-quality DNA starting material. Unlike plasmid DNA, synthetic DNA can be produced rapidly without relying on bacterial fermentation, minimizing complexity and contamination risks. It also offers unparalleled flexibility and customization, allowing researchers to design exactly the sequences they need without limitations. These advantages make synthetic DNA technology increasingly attractive as the field pushes toward scalable, high-purity, and demand-responsive DNA production.

Compared to other DNA synthesis methods, such as de-novo synthesis or PCR-based amplification, synthetic DNA offers high quality, purity, flexibility and scalability. 4basebio’s synthetic DNA platform can amplify long sequences up to 20kb in length and produce large GMP batches to support advanced clinical programs. These advantages make synthetic DNA technology increasingly attractive as the field pushes toward scalable, high-purity, and demand-responsive DNA production.

Enzymatic DNA manufacturing process

4basebio’s synthetic DNA is produced using an enzymatic, cell-free manufacturing process powered by its proprietary primer-free DNA amplification technology, TruePrime®. Unlike conventional pDNA manufacturing, which relies on bacterial fermentation, cell growth, and downstream plasmid extraction, 4basebio’s approach eliminates the need for host cells entirely.

TruePrime® combines two unique enzymes to enable isothermal multiple displacement DNA amplification in a continuous, cell-free process, delivering high yields of high-quality DNA. 4basebio’s enzymes are produced in-house and have a higher fidelity compared to the wildtype, which ensures greater sequence accuracy and avoids supply chain issues.

This unique cell-free, enzymatic process offers greater control, scalability, and consistency compared to plasmid-based manufacturing, supporting reliable production of synthetic DNA tailored for advanced therapeutic applications. What makes 4basebio’s process unique is the removal of all bacterial sequences and producing our own master template before DNA amplification. This ensures no antibiotic resistance genes and unwanted plasmid DNA backbone sequences are incorporated, resulting in a cleaner and more defined DNA product.

6 icons on a timeline showing manufacturing process

Key benefits of synthetic DNA technology over plasmid DNA

4basebio’s synthetic DNA platform offers a range of benefits for modern DNA design and production. By leveraging cell-free, enzymatic processes, it provides precise, flexible, and reliable DNA constructs that can support a wide variety of applications. These benefits make it an ideal foundation for accelerating research and next-generation therapeutic programs.

get in touch today

Unlike pDNA, which is produced through bacterial fermentation, synthetic DNA is manufactured without the use of bacteria. This eliminates the risk of endotoxin contamination, antibiotic resistance genes, and residual host-cell impurities, resulting in a cleaner and inherently safer DNA product.
Plasmid DNA production relies on complex cell-based processes and often requires extensive downstream purification steps. This may extend manufacturing timelines and delay your therapeutic programs. In contrast, synthetic DNA is produced via a streamlined, cell-free process, enabling faster production and more rapid progression from design to delivery.
4basebio’s enzymatic manufacturing process uses a high-fidelity enzymatic process, ensuring sequence accuracy and high batch-to-batch consistency. It also offers a simplified manufacturing process compared to plasmid DNA, ensuring predictable and reproducible batches.
Due to the enzymatic nature of the process and there being no bacterial-fermentation steps included in the synthetic DNA manufacturing process, it is highly compatible with complex sequences such ad long polyA tails or ITRs/ LTRs. For certain applications, such as mRNA therapeutics, where long DNA sequences are often required, 4basebio’s synthetic DNA platform can incorporate sequences up to 20kb.
Synthetic DNA manufacturing allows flexibility when it comes to batch sizes. It allows us to produce small batches suitable for personalized cancer vaccines where small amounts are required for each patient. It’s also easily scalable and batches up to 10g are available for HQ and GMP-grade DNA projects.

Application-specific synthetic DNA constructs

Learn more

Image showing four DNA constructs. They are made using 4basebio's synthetic DNA technology.

We understand that advanced therapies each have unique production requirements. At 4basebio, we develop application-specific DNA constructs tailored to your needs, helping to optimize and streamline your workflows. Our synthetic DNA solutions support a wide range of cutting-edge applications, including mRNA vaccines and therapeutics, viral vectors, gene editing and DNA vaccines. By providing flexible, precise, and reliable DNA constructs, we help accelerate development and enhance manufacturing efficiency across the next generation of genetic medicines.